TY - JOUR T1 - Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of a nationwide serosurvey in the Netherlands JF - medRxiv DO - 10.1101/2021.03.29.21254334 SP - 2021.03.29.21254334 AU - SA McDonald AU - F Miura AU - ERA Vos AU - M van Boven AU - H de Melker AU - F van der Klis AU - R van Binnendijk AU - G den Hartog AU - J Wallinga Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254334.abstract N2 - Background The proportion of SARS-CoV-2 positive persons who are asymptomatic – and whether this proportion is age-dependent – are still open research questions. Because an unknown proportion of reported symptoms among SARS-CoV-2 positives will be attributable to another infection or affliction, the observed, or ‘crude’ proportion without symptoms may underestimate the proportion of persons without symptoms that are caused by SARS-CoV-2 infection.Methods Based on a large population-based serological study comprising test results on seropositivity and self-reported symptom history conducted in April/May 2020 in the Netherlands (n=3147), we estimated the proportion of reported symptoms among those persons infected with SARS-CoV-2 that is attributable to this infection, where the set of relevant symptoms fulfills the ECDC case definition of COVID-19, using inferential methods for the attributable risk (AR). Generalised additive regression modelling was used to estimate the age-dependent relative risk (RR) of reported symptoms, and the AR and asymptomatic proportion (AP) were calculated from the fitted RR.Results Using age-aggregated data, the estimated AP was 70% (95% CI: 65-77%). The estimated AP decreased with age, from 80% (95% CI: 67-100%) for the <20 years age-group, to 55% (95% CI: 48-68%) for the 70+ years age-group.Conclusion Whereas the ‘crude’ AP represents a lower bound for the proportion of persons infected with SARS-CoV-2 without COVID-19 symptoms, the AP as estimated via an attributable risk approach represents an upper bound. Age-specific AP estimates can inform the implementation of public health actions such as targetted virological testing and therefore enhance containment strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Health, Welfare and Sports (VWS), the Netherlands [grant number not applicable]. The views expressed are those of the authors and not necessarily those of VWS or the RIVM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for the PICO study was approved by the Medical Ethics Committee MEC-U, the Netherlands (Clinical Trial Registration NTR8473), and conformed to the principles embodied in the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data are accessible to researchers after publication and upon reasonable request for data sharing to the corresponding author. ER -